Medicines & Healthcare products Regulatory Agency

MHRA Regulating Medicines and Medical Devices

Response document for MHRA public consultation on the proposal to make Arthriex 750mg and 1500mg Film-coated Tablets available in Pharmacies **ANNEX 1**
Ref: ARM96

Your details

Name: British Society for Rheumatology's Osteoarthritis Special Interest Group

Position (if applicable):

Organisation (if applicable): British Society for Rheumatology

Email: policy@rheumatology.org.uk

a. Do you consider that Arthriex 750mg and 1500mg Film-coated Tablets should be available as a Pharmacy medicine?

Yes ☐ No ☒ Not sure ☐

Please provide any comments or evidence to support your response:

We are not aware of any positive studies performed with this preparation and NICE CG177 has determined there is no value in offering glucosamine, this preparation is not required.

b. Do you have any specific comments on the leaflet or the label provided in the public reclassification report? In particular:

- **If you are a potential patient, do you find the patient information leaflet (Annex 2) and the label (Annex 3) understandable?**
- **If you are a pharmacist or healthcare professional would you be confident to supply this product if suitable pharmacy training was provided?**

c. Do you have any other comments on the reclassification?

d. The MHRA may publish consultation responses. Do you want your response to remain confidential?

Yes ☐ Partially* ☐ No ☒

*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email (reclassification@mhra.gsi.gov.uk) to arrive by **xxxxxx 2017.** Contributions received after that date cannot be included in the exercise.